The Effect of Chronic Altitude Exposure on Chronic Obstructive Pulmonary Disease Outcomes in the SPIROMICS Cohort: An Observational Cohort Study.

Suri R, Markovic D, Woo H, Arjomandi M, Barr RG, Bowler RP, Criner G, Curtis JL, Dransfield MT, Drummond MB, Fortis S, Han MK, Hoffman EA, Kaner RJ, Kaufman JD, Krishnan JA, Martinez FJ, Ohar J, Ortega VE, Paine R, Soler X, Woodruff PG, Hansel NN, Cooper CB, Tashkin DP, Buhr RG, Barjaktarevic IZ. The Effect of Chronic Altitude Exposure on Chronic Obstructive Pulmonary Disease Outcomes in the SPIROMICS Cohort: An Observational Cohort Study. American journal of respiratory and critical care medicine. 2024 Nov 15; 210(10):1210-1218.

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.    Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions

Search for Abstract from PubMed

---

Abstract:

Individuals with chronic obstructive pulmonary disease (COPD) have airflow obstruction and maldistribution of ventilation. For those living at high altitude, any gas exchange abnormality is compounded by reduced partial pressures of inspired oxygen. Does residence at higher altitude exposure affect COPD outcomes, including lung function, imaging characteristics, symptoms, health status, functional exercise capacity, exacerbations, and mortality? From the SPIROMICS (Subpopulation and Intermediate Outcome Measures in COPD Study) cohort, we identified individuals with COPD living below 1,000?ft (305?m) elevation (? = 1,367) versus above 4,000?ft (1,219?m) elevation (? = 288). Multivariable regression models were used to evaluate associations of exposure to high altitude with COPD-related outcomes. Living at higher altitude was associated with reduced functional exercise capacity as defined by 6-minute-walk distance (-32.3?m [95% confidence interval, -49.8 to -14.8?m]). There were no differences in patient-reported outcomes as defined by symptoms (COPD Assessment Test and modified Medical Research Council dyspnea scale), or health status (St. George''s Respiratory Questionnaire). Higher altitude was not associated with a different rate of FEV decline. Higher altitude was associated with lower odds of severe exacerbations (incidence rate ratio, 0.65 [95% confidence interval, 0.46 to 0.90]). There were no differences in small airway disease, air trapping, or emphysema. In longitudinal analyses, higher altitude was associated with increased mortality (hazard ratio, 1.25 [95% confidence interval, 1.0 to 1.55]); however, this association was no longer significant when accounting for air pollution. Long-term altitude exposure is associated with reduced functional exercise capacity in individuals with COPD, but this did not translate into differences in symptoms or health status. In addition, long-term high-altitude exposure did not affect progression of disease as defined by longitudinal changes in spirometry. Clinical trial registered with www.clinicaltrials.gov (NCT01969344).